Millennium: The Takeda Oncology Company announced results from its Phase 3 study of Velcade (bortezomib) for injection for the treatment of newly diagnosed multiple myeloma patients after autologous stem cell transplant (ASCT). In this study, 370 patients were randomized to either Velcade consolidation therapy or no consolidation therapy following ASCT. The study showed that consolidation with Velcade led to significant improvements (P=0.037) in the median progression-free survival measured from the time of randomization, which was 27 months in the Velcade arm, compared with 20 months in the control group. Forty-five percent of patients in the Velcade arm achieved a complete response/near complete response, compared with 35% of patients in the control group (P<0.05). The estimated overall survival was 87% in both groups after a median follow-up of 27 months.

Velcade is a powder for IV injection after reconstitution and presently indicated for the treatment of multiple myeloma and mantle cell lymphoma in patients who have received at least one prior therapy. 

For more information call (866) VELCADE or visit